Navigation Links
Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vaccine Trial
Date:11/2/2007

ATLANTA, Nov. 2 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based biotechnology company, announced today excellent safety and immunogenicity data from its full-dose HIV/AIDS vaccine human trial which began in September 2006.

This full-dose trial is the second in a series of four Phase 1 human trials designed to test the safety and immunogenicity of the GeoVax HIV/AIDS vaccines. Involving 36 participants of which 30 received vaccine and 6 received placebo, this trial protocol included vaccination with two full-doses of GeoVax's DNA vaccine to prime the immune response followed by two full- doses of GeoVax's MVA vaccine to boost the immune response. GeoVax's DNA and MVA vaccines express over 50% of the AIDS virus (HIV-1) protein components in order to stimulate a broad anti-HIV immune response. The vaccines cannot cause AIDS because they do not include complete virus. A Phase 1 human trial, started in April 2006, evaluated the delivery of only 1/10th of the full dosage and utilized the same vaccine regimen evaluated in the full dose trial.

From data collected from the 26 participants who completed the trial, the following positive conclusions were observed:

-- GeoVax HIV/AIDS vaccines, both DNA and MVA, continue to demonstrate that they are quite safe and immunogenic following the delivery of the four full-doses (two of each vaccine) used in the trial's protocol

-- The full-dose regimen of GeoVax vaccines continues to be well tolerated without any type of reaction, mild or systemic, in the majority of participants

-- CD4 T-cell and CD8 T-cell responses are very evident both in the 1/10th dose and full-dose vaccine recipients

-- Antibody responses to the envelope glycoprotein (Env) increased following the fourth vaccination, and were present in 88% of the full-dose participants

-- Delivery of the fourth vaccination increased the frequency and magnitude of the CD8 T-cell and Antibody
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential
4. Avants Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential
5. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
6. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
7. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
8. Sygnis Pharma AG announces date for presentation of clinical results
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
11. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... N.Y. , Oct. 19, 2014  Henry Schein, ... provider of health care products and services to office-based ... it has invested in Iwase Dental Supply, Inc., a ... in Japan.  The transaction marks Henry Schein,s entrance into ... largest dental market, and increases to 28 the number ...
(Date:10/17/2014)... N.C. , Oct. 17, 2014 ... the Medical Affairs function has come across several ... resources efficiently and managing globalization.  ... Practices, LLC is dedicated to providing benchmarking and ... Medical Affairs Consortium is a service composed of ...
(Date:10/17/2014)... OAKS, Calif. , Oct. 17, 2014  Amgen ... of R. Sanders Williams , M.D., president of ... Mahley Distinguished Professor.  "We are pleased ... Amgen Board," said Robert A. Bradway , chairman ... and distinguished experience in academic medicine and his direct ...
Breaking Medicine Technology:Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5Early Key Findings from the Medical Affairs Consortium Research 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3
... 12 ,Micromet, Inc. (Nasdaq: MITI ) and ... treatment in a multi-center, phase 2 trial conducted ... adult acute lymphoblastic leukemia (ALL). Blinatumomab is a ... is only expressed,on B cells. The clinical development ...
... June 11 /Xinhua-PRNewswire-FirstCall/ --,Pharmaceutical company Pharmaxis (ASX: PXS; ... III clinical trial evaluating the safety of,Bronchitol in ... 12-month treatment period was an open label extension ... reported, showing that Bronchitol,improved quality of life and ...
Cached Medicine Technology:Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 2Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 3Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 4Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 5Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 6Pharmaxis Long-Term Safety Study of Bronchitol Completes 2
(Date:10/20/2014)... Washington, D.C. (PRWEB) October 20, 2014 Zereana ... was crowned Mrs. Maryland 2014 on a platform to think ... battle scars, and uses her position to raise awareness about ... on awareness for breast cancer. You say the color pink ... “But I know for a fact that it has not ...
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
(Date:10/20/2014)... Collins, CO (PRWEB) October 20, 2014 ... dGH assays are the only imaging assays capable ... in a single test.  With these three dimensions ... their ability to detect the widest range of ... translocations—mutations usually missed by other genomic tools, including ...
(Date:10/20/2014)... hard to imagine what it’s like to live without shoes, ... it’s a reality. And while new shoes are considered a ... barefoot on rocky terrain or sewage-lined streets just to collect ... , Buckner International's Shoes for Orphan Souls project ... encourage support for Air1 and while also providing new shoes ...
(Date:10/19/2014)... and Hastings, a Phoenix personal injury law firm with ... area and across Arizona reports record demand in 2014 ... Statistics have indicated a steady increase in automobile accidents ... and Hastings has seen a steady increase in the ... injured through no fault of their own that is ...
Breaking Medicine News(10 mins):Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3
... Medicare Claims Denials by 50% and IVANS LIME Is Ten Times ... ... 18, 2009 -- IVANS , the leading provider of corporate ... Verification solution has helped Mobile X-Ray Imaging Inc. significantly reduce ...
... DALLAS, Feb. 18 Every week more than 3,000 people in ... many find themselves with insufficient coverage or lack of insurance to ... , , The Limbs for Life Foundation ... and provide them with financial assistance to return to productive jobs ...
... their meat. Whether it,s rib eyes, pork chops or chicken ... country that more than 85 billion pounds of meat and ... a quarter of U.S. beef and pork is exported to ... the world,s largest consumer of meat, in Mexico, meat consumption ...
... pressure medication may be the key to preventing brain ... newly published study by researchers at Wake Forest University ... of an improved quality of life for cancer patients. ... a hypothesis from previous studies that a compound similar ...
... , A research group of the Universities of Granada ... food craving, an irresistible desire for eating certain foods (sweets, ... out by Professors Silvia Moreno Domnguez (University of ... and M Carmen Fernndez-Santaella ( University of Granada ...
... by Cop" (SBC) is a suicide method in which a ... an attempt to get oneself killed or injured by law ... Sciences examined the prevalence of this phenomenon among a ... SBC occurs at extremely high rates, with 36 percent of ...
Cached Medicine News:Health News:IVANS Helps Mobile X-Ray Imaging Inc. Reduce Its Costs for Uncompensated Care 2Health News:IVANS Helps Mobile X-Ray Imaging Inc. Reduce Its Costs for Uncompensated Care 3Health News:Limbs for Life Foundation to Host 8th Annual Fundraiser and Live Auction 2Health News:American Veterinary Medical Association: Weaving a Web for Food Safety 2Health News:Blood pressure compound may benefit brain tumor patients 2Health News:Blood pressure compound may benefit brain tumor patients 3Health News:Several studies prove self-banning certain foods may cause food craving 2Health News:'Suicide by cop' phenomenon occurring in over a third of North American shootings involving police 2
... The complete line of Surgical Access ...unlike ... ,The OnePort™ trocar system is actually four ... versatile, operationally flexible and clinically adaptive to ... options in disposability and bladed or dilating ...
... Surgical Access ...unlike any trocar system you've ... is actually four systems in one ... clinically adaptive to all of your needs., ... bladed or dilating tip styles, OnePort™ can ...
... Surgical Access ...unlike any trocar system you've ... is actually four systems in one ... clinically adaptive to all of your needs., ... bladed or dilating tip styles, OnePort™ can ...
... Pak contains: (1) 15mm obturator, ... (1) 12mm ENDOPATH thoracic trocar ... Pak contains: (1) 15mm obturator, ... ,FPK03 Thoracic Trocar Pak contains: ...
Medicine Products: